Cantor Fitzgerald set a $27.00 price objective on Halozyme Therapeutics (NASDAQ:HALO) in a research note issued to investors on Tuesday. The firm currently has a buy rating on the biopharmaceutical company’s stock.
Other analysts have also recently issued reports about the company. BidaskClub upgraded Halozyme Therapeutics from a hold rating to a buy rating in a research report on Wednesday, October 3rd. Piper Jaffray Companies reiterated a neutral rating on shares of Halozyme Therapeutics in a research report on Friday, October 19th. BMO Capital Markets upped their price target on Halozyme Therapeutics from $19.00 to $21.00 and gave the company a market perform rating in a research report on Wednesday, August 8th. ValuEngine upgraded Halozyme Therapeutics from a hold rating to a buy rating in a research report on Thursday, November 1st. Finally, Zacks Investment Research upgraded Halozyme Therapeutics from a hold rating to a buy rating and set a $19.00 price target on the stock in a research report on Wednesday, July 11th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company. Halozyme Therapeutics currently has a consensus rating of Hold and a consensus price target of $20.78.
Shares of NASDAQ HALO opened at $15.89 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.49 and a quick ratio of 3.43. The firm has a market capitalization of $2.28 billion, a P/E ratio of 35.31 and a beta of 1.88. Halozyme Therapeutics has a one year low of $14.33 and a one year high of $21.48.
Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, November 6th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.04. The business had revenue of $25.60 million during the quarter, compared to analyst estimates of $30.42 million. Halozyme Therapeutics had a return on equity of 18.82% and a net margin of 16.24%. Halozyme Therapeutics’s revenue was down 59.8% on a year-over-year basis. During the same period in the prior year, the company posted $0.02 earnings per share. Equities analysts anticipate that Halozyme Therapeutics will post -0.81 EPS for the current year.
In other news, major shareholder Randal J. Kirk sold 1,194,462 shares of the stock in a transaction on Thursday, August 23rd. The stock was sold at an average price of $17.65, for a total transaction of $21,082,254.30. Following the sale, the insider now owns 3,562,388 shares in the company, valued at $62,876,148.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Randal J. Kirk sold 303,168 shares of the stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $17.36, for a total value of $5,262,996.48. Following the sale, the insider now owns 3,562,388 shares in the company, valued at approximately $61,843,055.68. The disclosure for this sale can be found here. Insiders sold 2,793,946 shares of company stock worth $49,250,429 over the last quarter. Company insiders own 16.80% of the company’s stock.
Several hedge funds have recently made changes to their positions in HALO. Dimensional Fund Advisors LP bought a new stake in shares of Halozyme Therapeutics during the first quarter worth $7,167,000. UBS Group AG grew its holdings in shares of Halozyme Therapeutics by 121.8% during the first quarter. UBS Group AG now owns 183,556 shares of the biopharmaceutical company’s stock worth $3,595,000 after purchasing an additional 100,813 shares during the last quarter. Xact Kapitalforvaltning AB grew its holdings in shares of Halozyme Therapeutics by 26.1% during the first quarter. Xact Kapitalforvaltning AB now owns 18,369 shares of the biopharmaceutical company’s stock worth $360,000 after purchasing an additional 3,800 shares during the last quarter. Amalgamated Bank grew its holdings in shares of Halozyme Therapeutics by 19.3% during the second quarter. Amalgamated Bank now owns 19,053 shares of the biopharmaceutical company’s stock worth $321,000 after purchasing an additional 3,077 shares during the last quarter. Finally, First Quadrant L P CA grew its holdings in shares of Halozyme Therapeutics by 309.3% during the second quarter. First Quadrant L P CA now owns 100,933 shares of the biopharmaceutical company’s stock worth $1,703,000 after purchasing an additional 76,271 shares during the last quarter. Institutional investors own 84.63% of the company’s stock.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc, a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally. The company's human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Featured Article: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.